Shares in Minerva Neurosciences Inc. (NERV) tanked 72% after the company’s experimental drug roluperidone tailored for the treatment of schizophrenia did not meet …
Minerva Neurosciences Inc (NASDAQ:NERV) investors are overwhelmingly excited today after the biotech firm announced that it has entered into a binding term sheet …
